1. Scrip

Pfizer On Paxlovid: "There's Still A Long Way To Go"

 
• By Jessica Merrill

Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.

Pfizer silver logo
Pfizer updated investors on the launch of Paxlovid • Source: Shutterstock

Use of the COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) is picking up in the US after some initial challenges getting the antiviral to the right patients quickly, but there is still a lot of work to do on expanding access and educating physicians and patients about the treatment, Pfizer Inc. said during its first quarter sales and earnings call on 3 May.

The addition of Paxlovid and the COVID-19 vaccine Comirnaty, partnered with BioNTech SE, are providing a big boost to Pfizer's 2022 revenues, but investors are wondering how long the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.